Semaglutide
-
healthNew Study Links Wegovy to Nearly Fivefold Increase in Sudden Vision Loss Compared to Ozempic
Analysis of seven years of FDA data indicates Wegovy users face significantly higher risks of ischemic optic neuropathy compared to Ozempic patients.
-
healthKenya's Weight-Loss Boom: Shifting Beauty Standards Drive Medical Procedures
Kenya sees a surge in demand for weight-loss treatments, from drugs like Ozempic to surgical procedures, as societal views on beauty and health evolve.
-
healthFDA Cracks Down on 30 Telehealth Firms Over Illegal GLP-1 Marketing
The FDA has issued warning letters to 30 telehealth companies for misleading marketing of GLP-1 products, including false claims and obscured sourcing.
-
healthAnti-Obesity Drug Set for Drastic Price Drop Post-Patent
New study reveals blockbuster anti-obesity and diabetes drug, semaglutide, could cost as little as $3 per month to manufacture, offering hope for wider access.
-
healthNew Drug Class Shows Promise for Smoking Cessation and Weight Management
GLP-1 receptor agonists, primarily exenatide and semaglutide, demonstrate significant potential in aiding smoking cessation and managing weight gain.
-
healthWeight-Loss Drugs Show Promise in Heart Attack Recovery
New study reveals GLP-1 drugs may significantly improve recovery and reduce complications for heart attack patients, offering cardiovascular benefits beyond weight loss.
-
healthNew GLP-1 Pill Outperforms Oral Semaglutide in Diabetes Trial
A new daily oral GLP-1 pill, orforglipron, shows superior blood glucose control compared to oral semaglutide in Type 2 diabetes patients, according to a Phase III trial.
-
financeNovo Nordisk Boosts Irish Tablet Plant with €432 Million Investment
Novo Nordisk invests €432 million in its Athlone, Ireland facility to expand manufacturing capacity for oral GLP-1 therapies, meeting growing global demand.